J. Goldman & Co LP decreased its position in shares of Merus (NASDAQ:MRUS - Free Report) by 82.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 7,001 shares of the biotechnology company's stock after selling 33,499 shares during the period. J. Goldman & Co LP's holdings in Merus were worth $294,000 as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. Janus Henderson Group PLC lifted its stake in shares of Merus by 12.7% during the 4th quarter. Janus Henderson Group PLC now owns 21,290 shares of the biotechnology company's stock worth $894,000 after purchasing an additional 2,400 shares during the period. Deutsche Bank AG lifted its position in Merus by 0.4% during the fourth quarter. Deutsche Bank AG now owns 113,056 shares of the biotechnology company's stock worth $4,754,000 after buying an additional 416 shares during the period. DAFNA Capital Management LLC lifted its position in Merus by 9.5% during the fourth quarter. DAFNA Capital Management LLC now owns 451,804 shares of the biotechnology company's stock worth $18,998,000 after buying an additional 39,231 shares during the period. Baker BROS. Advisors LP boosted its stake in Merus by 50.0% in the 4th quarter. Baker BROS. Advisors LP now owns 450,000 shares of the biotechnology company's stock worth $18,922,000 after buying an additional 150,000 shares during the last quarter. Finally, Algert Global LLC grew its holdings in Merus by 12.6% in the 4th quarter. Algert Global LLC now owns 173,114 shares of the biotechnology company's stock valued at $7,279,000 after buying an additional 19,390 shares during the period. Institutional investors and hedge funds own 96.14% of the company's stock.
Analyst Ratings Changes
Several equities research analysts recently issued reports on the stock. Guggenheim reissued a "buy" rating and issued a $109.00 target price on shares of Merus in a research report on Friday, March 28th. Piper Sandler initiated coverage on Merus in a research report on Thursday, February 13th. They issued an "overweight" rating and a $84.00 target price on the stock. Wells Fargo & Company reduced their target price on Merus from $91.00 to $89.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. HC Wainwright restated a "buy" rating and issued a $85.00 price objective on shares of Merus in a report on Monday, March 3rd. Finally, Bank of America reduced their price objective on Merus from $73.00 to $70.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $85.15.
Get Our Latest Report on Merus
Merus Price Performance
MRUS traded up $1.48 on Friday, reaching $41.56. The company's stock had a trading volume of 1,063,461 shares, compared to its average volume of 720,344. Merus has a 1 year low of $33.19 and a 1 year high of $61.61. The business's 50 day moving average is $42.96 and its 200 day moving average is $43.76. The stock has a market cap of $2.88 billion, a price-to-earnings ratio of -10.52 and a beta of 0.94.
Merus (NASDAQ:MRUS - Get Free Report) last released its earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.23). The business had revenue of $26.49 million for the quarter, compared to analysts' expectations of $7.82 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. As a group, research analysts forecast that Merus will post -3.85 earnings per share for the current fiscal year.
About Merus
(
Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Further Reading
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
